医药代表登记备案 (yīyào dàibiǎo dēngjì bèiàn):Platform for registration of pharmaceutical company representatives

The China Food and Drug Administration and National Health and Family Planning Commission have jointly issued a document on the registration of representatives of pharmaceutical companies for public opinions.

The document stipulates that representatives of pharmaceutical companies can only engage in academic promotion, technical consultation and other activities, and must not seek to sell the companies' products.

According to the document, the personal information of pharmaceutical company representatives including their names, photos and identification card numbers will be registered and kept on record. The license holders of pharmaceutical drugs, usually the manufacturers, should register their records and the details of their authorized representatives on the platform.

The platform, which is being established by the China Food and Drug Administration, will make public pharmaceutical companies or their sales representatives that violate regulations or have a bad credit history.

The new regulation forbids the representatives of pharmaceutical companies from being involved in sales or misleading doctors about the efficacy of products by exaggerating the curative effects or concealing the adverse effects.